Advertisement

Breast Cancer Research and Treatment

, Volume 165, Issue 2, pp 455–465 | Cite as

Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens

  • Xi Tan
  • Tareq Fabian Camacho
  • Virginia T. LeBaron
  • Leslie J. Blackhall
  • Rajesh BalkrishnanEmail author
Epidemiology

Abstract

Purpose

To explore differences in opioid use across different adjuvant endocrine therapy (AET) regimens, factors associated with opioid use, and the impact of opioid use on overall survival in female breast cancer patients treated with AET.

Methods

This retrospective study analyzed 2006–2012 SEER-Medicare datasets, following patients for at least two years from the index date, defined as the first date they filled an AET prescription. The study included adult women with incident, primary, hormone-receptor-positive, stage I–III breast cancer. They were also first-time AET users, and fee-for-service Medicare enrollees continuously enrolled in Medicare Parts A, B, and D. The main independent variable was the AET regimen. We measured whether patients used opioids after the initiation of AET.

Results

After the adjustment of inverse probability treatment weights and unbalanced covariates, the average treatment effect probabilities of opioid use were similar between those who used aromatase inhibitors (AI) only and those used tamoxifen (TAM) only (56.2 vs. 55.3%, respectively). Opioid use probabilities for those who switched from AI to TAM were higher than those for the TAM-only and AI-only groups. Opioid use was also significantly associated with AET non-adherence. Opioid users had a significantly higher risk of death (adjusted hazard ratio [HR] = 1.59, p < 0.001).

Conclusions

Switching from AI to TAM was associated with a high likelihood of opioid use. Opioid use was significantly associated with AET non-adherence and higher risk of mortality in female Medicare beneficiaries with breast cancer even after adjusting for adherence.

Keywords

Opioid Adjuvant endocrine therapy Breast cancer Medicare Tamoxifen Aromatase inhibitor 

Notes

Compliance with ethical standards

Conflict of interest

The authors declared no conflicts of interest.

References

  1. 1.
    Johannsen M, Christensen S, Zachariae R, Jensen AB (2015) Socio-demographic, treatment-related, and health behavioral predictors of persistent pain 15 months and 7–9 years after surgery: a nationwide prospective study of women treated for primary breast cancer. Breast Cancer Res Treat 152(3):645–658. doi: 10.1007/s10549-015-3497-x CrossRefPubMedGoogle Scholar
  2. 2.
    Runowicz CD, Leach CR, Henry NL et al (2016) American cancer society/american society of clinical oncology breast cancer survivorship care guideline. CA Cancer J Clin 66(1):43–73. doi: 10.3322/caac.21319 CrossRefPubMedGoogle Scholar
  3. 3.
    International Association for the Study of Pain (2009). Epidemiology of Cancer Pain. http://www.iasp-pain.org/files/Content/ContentFolders/GlobalYearAgainstPain2/CancerPainFactSheets/Epidemiology_Final.pdf. Accessed 27 Apr 2017
  4. 4.
    Tan X, Marshall VD, Anderson RT, Donohoe J, Camacho F, Balkrishnan R (2015) Adjuvant therapy use among Appalachian breast cancer survivors. Medicine (Baltimore) 94(26):e1071CrossRefGoogle Scholar
  5. 5.
    Coleman RE, Bolten WW, Lansdown M et al (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34(3):275–282CrossRefPubMedGoogle Scholar
  6. 6.
    The ATAC Trialists’ Group (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for earlystage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633–643CrossRefGoogle Scholar
  7. 7.
    Dent SF, Gaspo R, Kissner M, Pritchard KI (2011) Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat 126(2):295–310. doi: 10.1007/s10549-011-1351-3 CrossRefPubMedGoogle Scholar
  8. 8.
    Gaillard S, Stearns V (2011) Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 13(2):205. doi: 10.1186/bcr2818 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lintermans A, Van Asten K, Wildiers H et al (2014) A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Res Treat 146(1):109–116. doi: 10.1007/s10549-014-2986-7 CrossRefPubMedGoogle Scholar
  10. 10.
    Bossart M, Becker M, Hadji P, Kieback DG, Hasenburg A (2012) Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial. Anticancer Res 32(9):3933–3938PubMedGoogle Scholar
  11. 11.
    Chang WP, Lin CC (2015) Use of opioid analgesics or sleeping medication and survival of cancer patients. Eur J Oncol Nurs 19(3):199–206. doi: 10.1016/j.ejon.2014.11.007 CrossRefPubMedGoogle Scholar
  12. 12.
    Dodd M, Janson S, Facione N et al (2001) Advancing the science of symptom management. J Adv Nurs 33(5):668–676CrossRefPubMedGoogle Scholar
  13. 13.
    Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619CrossRefPubMedGoogle Scholar
  14. 14.
    Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1258–1267CrossRefPubMedGoogle Scholar
  15. 15.
    Muller CJ, MacLehose RF (2014) Estimating predicted probabilities from logistic regression: different methods correspond to different target populations. Int J Epidemiol 43(3):962–970. doi: 10.1093/ije/dyu029 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    SAS Institute, Inc (2011) SAS/STAT user’s guide, v. 9.3. https://support.sas.com/documentation/cdl/en/statug/63962/PDF/default/statug.pdf. Accessed 27 Apr 2017
  17. 17.
    McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF (2013) A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 32(19):3388–3414CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    McCaffrey D, Burgette L, Griffin BA, Craig Martin (2016) Propensity scores for multiple treatments: a tutorial for the MNPS macro in the twang SAS macros. Rand Corporation. https://www.rand.org/pubs/tools/TL169z1.readonline.html. Accessed 27 Apr 2017
  19. 19.
    Wei G, Schaubel DE (2008) Estimating cumulative treatment effects in the presence of nonproportional hazards. Biometrics 64:724–732CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang X, Loberiza FR, Klein JP, Zhang MJ (2007) A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Progr Biomed 88(2):95–101CrossRefGoogle Scholar
  21. 21.
    Zucker DM (1998) Restricted mean life with covariates: modification and extension of a useful survival analysis method. J Am Stat Assoc 93:702–708CrossRefGoogle Scholar
  22. 22.
    Kumar VA, Sidell MA, Jones JP, Vonesh EF (2014) Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system. Kidney Int 86(5):1016–1022. doi: 10.1038/ki.2014.224 CrossRefPubMedGoogle Scholar
  23. 23.
    Calip GS, Xing S, Jun DH, Lee WJ, Hoskins KF, Ko NY (2017) Polypharmacy and adherence to adjuvant endocrine therapy for breast cancer. J Oncol Pract. doi: 10.1200/JOP.2016.018317 PubMedGoogle Scholar
  24. 24.
    Taketani K, Tokunaga E, Yamashita N et al (2014) The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. Surg Today 44(10):1841–1846. doi: 10.1007/s00595-013-0762-7 CrossRefPubMedGoogle Scholar
  25. 25.
    Chim K, Xie SX, Stricker CT et al (2013) Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 13:401. doi: 10.1186/1471-2407-13-401 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Jarlbaek L, Hansen DG, Bruera E, Andersen M (2010) Frequency of opioid use in a population of cancer patients during the trajectory of the disease. Clin Oncol (R Coll Radiol) 22(3):199–207. doi: 10.1016/j.clon.2009.12.002 CrossRefGoogle Scholar
  27. 27.
    Schreiber KL, Martel MO, Shnol H et al (2013) Persistent pain in postmastectomy patients: comparison of psychophysical, medical, surgical, and psychosocial characteristics between patients with and without pain. Pain 154:660–668CrossRefPubMedGoogle Scholar
  28. 28.
    Peuckmann V, Ekholm O, Rasmussen NK et al (2007) Health-related quality of life in long-term breast cancer survivors: nationwide survey in Denmark. Breast Cancer Res Treat 104:39–46CrossRefPubMedGoogle Scholar
  29. 29.
    Kurita GP, Sjøgren P (2015) Pain management in cancer survivorship. Acta Oncol 54(5):629–634CrossRefPubMedGoogle Scholar
  30. 30.
    Mao J, Su H, Feng R et al (2011) Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res Treat 13(1):R8CrossRefGoogle Scholar
  31. 31.
    Niravath P (2013) Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 24(6):1443–1449. doi: 10.1093/annonc/mdt037 CrossRefPubMedGoogle Scholar
  32. 32.
    Stevens RA, Ghazi SM (2000) Routes of opioid analgesic therapy in the management of cancer pain. Cancer Control 7(2):132–141PubMedGoogle Scholar
  33. 33.
    Gagnon B, Scott S, Nadeau L, Lawlor PG (2015) Patterns of community-based opioid prescriptions in people dying of cancer. J Pain Symptom Manag 49(1):36.e1–44.e1. doi: 10.1016/j.jpainsymman.2014.05.015 CrossRefGoogle Scholar
  34. 34.
    Lindsay TH, Jonas BM, Sevcik MA et al (2005) Pancreatic cancer pain and its correlation with changes in tumorvasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. Pain 119(1–3):233–246CrossRefPubMedGoogle Scholar
  35. 35.
    Cronin-Fenton DP, Heide-Jørgensen U, Ahern TP et al (2015) Opioids and breast cancer recurrence: a Danish population-based cohort study. Cancer 121(19):3507–3514. doi: 10.1002/cncr.29532 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of Pharmaceutical Systems and Policy, School of PharmacyWest Virginia UniversityMorgantownUSA
  2. 2.Department of Public Health Sciences, School of MedicineUniversity of VirginiaCharlottesvilleUSA
  3. 3.Department of Acute & Specialty Care, School of NursingUniversity of VirginiaCharlottesvilleUSA
  4. 4.Department of Internal Medicine, School of MedicineUniversity of VirginiaCharlottesvilleUSA

Personalised recommendations